Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH
Quick facts
Phase 3 pipeline
- Rituximab sc · Oncology, Immunology
Rituximab is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion through antibody-dependent cellular cytotoxicity and direct apoptosis.
Phase 2 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH portfolio CI brief
- Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH pipeline updates RSS
Frequently asked questions about Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH
What is Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH's pipeline?
Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH has 1 drugs in Phase 3, 1 in Phase 2, 0 in Phase 1. Late-stage candidates include Rituximab sc.
Related
- Sector hub: All tracked pharma companies